PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.36%
Net income growth 1.25-1.5x AXSM's 9.19%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
-22.93%
Negative yoy D&A while AXSM is 3.81%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
18.38%
Deferred tax of 18.38% while AXSM is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-40.28%
Both cut yoy SBC, with AXSM at -19.76%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
112.09%
Well above AXSM's 14.68% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.72%
A yoy AP increase while AXSM is negative at -56.06%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
300.21%
Lower 'other working capital' growth vs. AXSM's 620.80%. David Dodd would see fewer unexpected short-term demands on cash.
-40.28%
Negative yoy while AXSM is 1.72%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
17.79%
Operating cash flow growth above 1.5x AXSM's 9.15%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
19.38%
Some CapEx rise while AXSM is negative at -6.13%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.99%
Growth of 99.99% while AXSM is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
98.29%
We have mild expansions while AXSM is negative at -6.13%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
684.38%
Stock issuance far above AXSM's 100.00%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.